RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Rua Life Sciences Stock

Rua Life Sciences Stocks 2024

Rua Life Sciences Stocks

22.18 M

Ticker

RUA.L

ISIN

GB0033360586

WKN

121857

In 2024, Rua Life Sciences had 22.18 M outstanding stocks, a 0% change from the 22.18 M stocks in the previous year.

The Rua Life Sciences Stocks history

YEARNUMBER OF STOCKS (undefined GBP)
2026e22.18
2025e22.18
2024e22.18
202322.18
202222.18
202117.7
202014.77
201912.98
20185.59
20175.89
20165.33
20155.12
20145.12
20135.12
20124.86
20114.86
20104.86
20094.86
20084.51
20073.83
20063.83
20053.83
20043.83

Rua Life Sciences shares outstanding

The number of shares was Rua Life Sciences in 2023 — This indicates how many shares 22.185 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Rua Life Sciences earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Rua Life Sciences's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Rua Life Sciences’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Rua Life Sciences's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Rua Life Sciences Aktienanalyse

What does Rua Life Sciences do?

Rua Life Sciences PLC is a British company specializing in the development and manufacture of therapeutics and medical devices in the pharmaceutical industry. It was founded in 1999 by Dr. Ahmed Abdullah as Research Chemicals International. In 2007, it was renamed Rua Life Sciences PLC and has been listed on the London Stock Exchange since 2014. The business model of Rua Life Sciences PLC is the research and development of pharmaceuticals. The company invests in the discovery of new active substances and technologies that can be used to treat diseases. In addition, Rua Life Sciences PLC is also involved in the storage and transportation of pharmaceutical products. The product range of Rua Life Sciences PLC includes various areas such as oncology, neurology, ophthalmology, infectious diseases, and cardiovascular diseases. In oncology research, the company works on innovative approaches to the treatment of various types of cancer. This includes the development of drugs to combat breast cancer or lung cancer. In neurology, Rua Life Sciences PLC aims to develop new therapeutics for the treatment of diseases of the nervous system. This includes, among other things, drugs for the relief of Parkinson's or Alzheimer's. In the field of ophthalmology, the company researches drugs for the treatment of eye diseases such as macular degeneration, which leads to vision impairment in older people. This also includes testing new technologies such as the combination of drugs with special apparatus. In infectious diseases research, Rua Life Sciences PLC works on drugs to combat viruses and bacteria that can cause various diseases. This also includes the development of vaccines to counter epidemic outbreaks. Another important area for Rua Life Sciences PLC is research in the field of cardiovascular diseases. The company is working on drugs to treat hypertension, heart attacks, and other cardiovascular diseases. In addition to pharmaceutical products and therapeutics, Rua Life Sciences PLC also offers medical devices. These include blood glucose meters and medical inhalers used in the treatment of respiratory diseases. The company aims to help patients worldwide and save lives. It invests large sums in the research and development of therapeutics and medical devices to improve healthcare for humans and animals. Rua Life Sciences PLC collaborates with leading scientists and biomedical companies and maintains a network of partners around the world. Overall, Rua Life Sciences PLC is a company with a wide product range specializing in the manufacture of pharmaceuticals and medical devices. The company is committed to healing diseases and improving the health of people worldwide. Rua Life Sciences ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Stocks Details

Evaluating Rua Life Sciences's Shares Outstanding

Rua Life Sciences's shares outstanding refer to the total number of shares that are currently held by all its shareholders, including institutional investors and restricted shares held by the company’s officers and insiders. The number of shares outstanding is crucial in determining the company's market capitalization and is used by investors to assess the company’s size, financial health, and investment potential.

Year-to-Year Comparison

Tracking the changes in Rua Life Sciences’s shares outstanding over the years can provide investors with insights into the company's financial strategies and market valuation. An increase in shares outstanding can result from actions like issuing new shares, while a decrease can result from buybacks.

Impact on Investments

For investors, understanding Rua Life Sciences’s shares outstanding is essential for evaluating its earnings per share (EPS) and market valuation. A change in the number of shares outstanding can impact the EPS, which is a significant driver of stock prices and investor decisions.

Interpreting Changes in Shares Outstanding

Variances in Rua Life Sciences’s shares outstanding can signal shifts in the company’s financial strategy. An increase may dilute the EPS and share value, indicating potential fundraising or acquisitions. Conversely, a decrease, often due to share buybacks, can enhance share value and indicate the company’s confidence in its financial performance.

Frequently Asked Questions about Rua Life Sciences stock

How many stocks are there of Rua Life Sciences?

The current number of stocks of Rua Life Sciences is 22.18 M undefined.

What does Number of Shares / OutstandingShares mean?

The outstanding shares (or issued shares) of Rua Life Sciences are the total number of shares issued and actively held by shareholders - both external investors and company insiders. However, these must be actual shares. may grant stock options to executives that can be converted into shares.

How has the number of shares of Rua Life Sciences evolved in recent years?

The number of shares of Rua Life Sciences has increased by 0% gestiegen compared to last year.

What does the number of shares mean for investors?

The number of shares outstanding is used to calculate key metrics such as a company's market capitalization, earnings per share (EPS), and cash flow per share (CFPS). The number of outstanding shares of a company is not static and can fluctuate greatly over time.

Why does the number of stocks fluctuate?

There are various factors that can lead to a change. Rua Life Sciences as a company can issue new shares, carry out stock splits or reverse splits.

Does the number of shares have an impact on the performance of Rua Life Sciences?

There is no tangible long-term evidence or study that stocks with a certain number of shares (regardless of Mega/Large/Mid/Small Cap) would yield significantly higher returns than others. There are occasional small studies (limited number of stocks, short investment period) that certain classes outperform or have higher risk, but none of them are 1. conclusive (cause-effect is unclear, experiment is not repeatable) or 2. generalizable (generalization is not possible due to small sample size and time period).

How much dividend does Rua Life Sciences pay?

Over the past 12 months, Rua Life Sciences paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Rua Life Sciences is expected to pay a dividend of 0 GBP.

What is the dividend yield of Rua Life Sciences?

The current dividend yield of Rua Life Sciences is .

When does Rua Life Sciences pay dividends?

Rua Life Sciences pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Rua Life Sciences?

Rua Life Sciences paid dividends every year for the past 0 years.

What is the dividend of Rua Life Sciences?

For the upcoming 12 months, dividends amounting to 0 GBP are expected. This corresponds to a dividend yield of 0 %.

In which sector is Rua Life Sciences located?

Rua Life Sciences is assigned to the 'Health' sector.

Wann musste ich die Aktien von Rua Life Sciences kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Rua Life Sciences from 8/27/2024 amounting to 0 GBP, you needed to have the stock in your portfolio before the ex-date on 8/27/2024.

When did Rua Life Sciences pay the last dividend?

The last dividend was paid out on 8/27/2024.

What was the dividend of Rua Life Sciences in the year 2023?

In the year 2023, Rua Life Sciences distributed 0 GBP as dividends.

In which currency does Rua Life Sciences pay out the dividend?

The dividends of Rua Life Sciences are distributed in GBP.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Rua Life Sciences

Our stock analysis for Rua Life Sciences Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Rua Life Sciences Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.